Amerikanische Gesellschaft für Hirudotherapie

Continuous postoperative monitoring of cutaneous free flaps using near infrared spectroscopy.

Research article published in Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2007)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportKlinische StudienRepez et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2007

Abstract

UNLABELLED: Reliable detection of circulatory compromise threatening free-flap viability is essential for prompt surgical intervention and flap salvage. Numerous techniques have been developed to address the issue of postoperative flap monitoring but none have achieved universal acceptance. Near infrared spectroscopy (NIRS) is a noninvasive technique that allows continuous monitoring of tissue oxygenation and perfusion. It is increasingly recognised to be a reliable method for flap viability assessment. This study was designed to investigate the ability of NIRS to detect and identify microvascular thrombosis endangering flap survival. To our knowledge, this is the first clinical evaluation of NIRS used for continuous monitoring of free flaps. METHODS: Fifty flaps used for autologous breast reconstruction in 48 patients were included in this prospective clinical study. NIRS was employed for 72-h continuous postoperative monitoring. The data were compared to findings of clinical assessments. RESULTS: Ten flaps (20%) developed 13 anastomosis thromboses (two arterial and 11 venous). NIRS detected all cases of flow failure prior to clinical observation with no false positives or negatives. Based on consistent patterns of NIRS parameter changes, it was possible to differentiate between changes caused by arterial and venous thrombosis with accuracy before surgical re-exploration. The salvage rate was 70%. Overall flap viability was 94%. CONCLUSIONS: Continuous NIRS monitoring can reliably detect and identify early stages of arterial and venous thrombosis, and is a credible method for noninvasive postoperative flap surveillance. Based on these findings, we advocate its use for monitoring of flaps with a cutaneous component.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEvaluation StudyJournal Article
Indexed MeSH termsAdultFemaleGraft RejectionGraft SurvivalHumansMammaplastyMiddle AgedPostoperative CarePostoperative ComplicationsProspective StudiesSpectroscopy, Near-InfraredSurgical Flaps

Zusammenfassung

Reliable detection of circulatory compromise threatening free-flap viability is essential for prompt surgical intervention and flap salvage. Numerous techniques have been developed to address the issue of postoperative flap monitoring but none have achieved universal acceptance.

Warum dies für die Hirudotherapie relevant ist

This prospective clinical study evaluated near-infrared spectroscopy (NIRS) for continuous postoperative monitoring of 50 free flaps used for autologous breast reconstruction in 48 patients over 72 hours. NIRS detected all 13 anastomosis thromboses (2 arterial, 11 venous) before clinical observation with no false positives or negatives, achieving a 70% salvage rate and 94% overall flap viability. The abstract concludes that continuous NIRS monitoring reliably detects early arterial and venous thrombosis and advocates its use for monitoring flaps with a cutaneous component. The abstract contains no mention of leeches, hirudotherapy, or any leech-related content. There is no defensible leech link from this abstract.

Zitation

Continuous postoperative monitoring of cutaneous free flaps using near infrared spectroscopy.

Repez et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2007

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.